Having trouble viewing this email? View in your browser.
 
Weekly News
04 January 2022

Dear colleagues,

We at ESCMID wish you a happy and safe new year!
Please find below the latest edition of ESCMID Weekly News.

With kind regards,
ESCMID Executive Office.

 
ESCMID 2022 Postgraduate Education Courses open for registration

Have you planned your learning journey for 2022? Be sure to check out the ESCMID Online and Onsite courses and workshops planned for 2022!

We look forward to seeing you at an ESCMID Educational Event in the near future!

 
 
ESCMID Special Funded Observership Call (Mayo Clinic)

Today opens the call for one ESCMID funded Observership at the Mayo Clinic (Rochester, Minnesota, USA). Send your application now and benefit from this prestigious Observership in Summer 2022. The call is open until 27 January 2022 and is open for ESCMID Young Scientist Members only. 

ESCMID CAREer Grant 2022: apply now!

The call to apply to the ESCMID CAREer Grant 2022 will close soon!

There is time until is 10 January 2022 to submit your application.

For the complete funding scheme, eligibility criteria and the application procedure, please visit the official ESCMID CAREer Grant webpage.

Free ecraid webinar - 19 January 2022, 13:00 CET

Be sure to register for the webinar ‘How clinical trials inform antimicrobial stewardship’, which will provide an overview of data from clinical trials in the management of cUTIs and pneumonia, and how this information may be incorporated into AMS activities.

ESCMID is a proud member of ecraid.

DEADLINE EXTENDED – ESCMID AMS Certificate 2022 – 2024

The Antimicrobial Stewardship Certificate Programme is a newly-planned educational programme in the field of AMS. Information on how to submit a course proposal can be found here.

Submission deadline:  Friday, 28 January 2022 at 23:59 CET

ESCMID Omicron update – available on demand!

Did you miss the ESCMID Omicron variant update webinar on 22 December 2021? Be sure to catch the replay on the ESCMID eAcademy website now, featuring insights from COVID-19 experts from across Europe, moderated by members of the ESCMID Executive Committee.

Persistence of the neutralising antibodies after SARS-CoV-2 infection

This study explored neutralising antibody levels in patients who had recovered from COVID-19 by analyzing the titre of antibodies associated with predicting immune status in individuals with natural infection. The results can provide evidence for developing vaccination schedules for these people.